Loading
companiesCompany
Laminar Pharmaceuticals
Laminar Pharmaceuticals is a Spain-based biotechnology company running 2 late-stage cancer trials of LAM561 in glioma & glioblastoma.
Overview
Laminar Pharmaceuticals, based in Palma de Mallorca, Spain, is a biotechnology company. Laminar Pharma is a biopharmaceutical company developing 'melitherapy', a therapeutic approach targeting membrane lipids rather than proteins or DNA, for conditions including cancer and Alzheimer's disease. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing LAM561 in glioma & glioblastoma. The largest, NCT04250922 (LAM561 With RT and TMZ for Adults With Glioblastoma), plans to enrol 144 participants (actual). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Palma de Mallorca, ES
Scorecard
All companies#378of 1244 companies, score 10
- phase 3 +3
- targets +2
- modalities +2
- registry trials +3
0 approved, 1 in phase 3, 0 earlier, 1 targets, 3 registry studies. Formula on the scorecards page.
Type
Stage
Growth stage
Website
Phase 3small molecule
LAM561 is an experimental small-molecule drug from Laminar Pharmaceuticals in phase 3 trials for glioma & glioblastoma, aimed at MET.